Allergan, Inc.

Allergen, Inc.

John T Trogden

Robert T Lyons

Chetan Pujara

Adnan K Salameh

Scott M Whitcup

Anuradha V Gore

Jaya Giyanani

James Nienyuan Chang

Michael R Robinson

Rhett M Schiffman

Kevin S Warner

Mayssa Attar

Pramod Sarpotdar

Guang Wei Lu

Kristin B Prinn

Ronald Bradford

Andrea S Kim

Chetan P Pujara

Patrick Michael Hughes

Gerald Woodrow DeVries

Patrick M Hughes

Hongwen Ma Rivers

Werhner C Orilla

Gerald W De Vries

Gerald W Devries

Adnan K Salamah

Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25&#xb0; C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25&#xb0; C. is in the range of from about 80,000 cps to about 300,000 cps.

High viscosity macromolecular compositions for treating ocular conditions

The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.

Androgen composition for treating an ophthalmic condition

Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.

Non-irritating testosterone emulsions

Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I 

Topical compositions comprising bimatoprost and methods for stimulating hair growth therewith

Compositions and methods for stimulating hair growth

Androgen composition for treating an opthalmic condition

Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.

Pharmaceutical compositions

Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25&#xb0; C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

Peripherally administered viscous formulations

Ocular implant delivery assemblies are provided which include a cannula having a lumen extending therethrough, a proximal end, a proximal end opening, a distal end, a distal end opening, and a lumen extending through the cannula. A cap is provided having a closed distal end, being in contact with the outer wall of the cannula, and covering the distal end and the distal end opening of the cannula, the cap being structured to allow the distal end and the distal end opening of the cannula to pass through the cap as the cannula is passed into an eye. An ocular implant is located in the lumen. The implant may be sealed in the cannula without the addition of a liquid carrier or it may be contained in a liquid carrier medium in the cannula. The implant may be made up of a number of microparticles having different compositions or different forms. The assembly also includes a sleeve located on the proximal end of the cannula and suitable for coupling the assembly to a syringe containing a pushing gel.

Ocular implant delivery assemblies with distal caps

Growing community of inventors

Villa Park, CA, United States of America

John T Trogden